Anti-Human IL-12 (Clone 24910) - 25 µg

ICC, N, WB

IL-12

Next Day Ambient

IL-12 plays a role in resistance against pathogens via the differentiation of naive T cells into Th1 cells. It stimulates the growth and function of T cells, blocks formation of new blood vessels, and contributes to antimycobacterial immune response. In addition, it promotes the production of IFN-γ and TNF-α and reduces IL-4 mediated suppression of IFN-γ. Consequently, this enhances the immunostimulatory and immunomodulatory effects of IFN-γ. In addition, there appears to be a link between IL-2 and the signal transduction of IL-12 in NK cells, which enhances the functional response of IL-12 via IFN-γ production and killing of target cells. Furthermore, IL-12 is thought to be associated with autoimmunity. IL-12 was shown to worsen the condition when administered to people already suffering from autoimmune diseases. Comparatively, inhibition of IL-12 (either through IL-12 gene knock-out in mice or treatment of mice with IL-12 mAbs) improved the disease.

Neutralization: Human IL-12 stimulates the ³H-thymidine incorporation by PHA activated human peripheral blood mononuclear cells in a dose-dependent manner¹. The ED₅₀ for this effect is typically 0.05 - 0.2 ng/mL. This antibody is useful for neutralization of Human IL-12 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human IL-12 (at 1.0 ng/ml) is 0.3 - 0.9 µg/ml. The bioassay was perfromed using PHA-activated peripheral blood mononuclear cell (PBMC) proliferation assay.
Immunocytochemistry: This antibody can be used at 8 - 25 μg/mL with the appropriate secondary reagent such as PN:M103 to detect human IL-12 in cultured cells or tissue sections using PN:K107 or PN:D100.

Other Molecules

AB_2830645

< 0.1 EU/µg

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.